News

Nov 7

2019

PHANES AND FOSUN KITE FORM STRATEGIC ALLIANCE FOR INNOVATIVE CAR-T PRODUCTS TO TREAT SOLID TUMORS

Phanes Therapeutics and Phanes Biopharmaceuticals (“Phanes”) recently formed an important strategic alliance with Fosun Kite Biotechnology (“Fosun Kite”). Under the...
Read More

Sep 17

2019

PHANES AND HANMI ANNOUNCE LICENSING AGREEMENT TO DEVELOP BI- AND/OR MULTI-SPECIFIC ANTIBODIES

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has signed a...
Read More

Jul 24

2019

MERCK TO PROVIDE BIORELIANCE® END-TO-END SOLUTIONS TO PHANES THERAPEUTICS

Collaboration to accelerate development and manufacturing of Bispecific Antibody Merck plans to offer Phanes a full suite of products and...
Read More

Mar 13

2018

CROWNBIO ENTERS STRATEGIC PARTNERSHIP WITH PHANES THERAPEUTICS TO ACCELERATE DISCOVERY AND DEVELOPMENT OF PHANES’ NOVEL ONCOLOGY AGENTS

Original link: https://blog.crownbio.com/press/partnership-with-phanes (San Diego, Calif., March 13, 2018) — Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:...
Read More

Dec 14

2017

WUXI BIOLOGICS AND PHANES ANNOUNCE STRATEGIC PARTNERSHIP

Shanghai and San Diego, Dec. 14, 2017 — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering...
Read More